Desmopressin

Desmopressin occupies a different position in this corpus than most peptides on the site. It is not a research-only or compounded-pharmacy molecule; it is a prescription drug with four FDA-approved indication clusters spanning 1978 to the present, listed on the WHO Model List of Essential Medicines, and supported by roughly fifty years of clinical-pharmacology characterization. The framing problem is not whether desmopressin works for its labeled indications — that case is settled by regulatory history and large clinical experience — but how the indications, routes, and dosing differ, and how iatrogenic hyponatremia interacts with each use case.

The first indication, central (neurogenic) diabetes insipidus, traces to the 1976 Robinson report and accumulated rapidly into clinical practice. CDI results from impaired posterior-pituitary AVP secretion — typically post-surgical, post-traumatic, or idiopathic-autoimmune — and produces polyuria, polydipsia, and dilute urine. Desmopressin restores the antidiuretic signal at the collecting duct; the Robinson 1976 NEJM report showed that 5–20 µg intranasal doses produced 8–20 hours of antidiuresis in patients with complete CDI. Modern CDI dosing spans oral tablets (commonly 0.1–0.4 mg two to three times daily), intranasal spray (the conventional DDAVP nasal spray at 10 µg per spray, typically 10–40 µg daily in divided doses), and the parenteral routes for hospitalized patients. The pharmacokinetic profile is route-dependent: bioavailability is substantially higher subcutaneously than orally (oral bioavailability is on the order of 0.1%, intranasal in the range of a few percent), and dose conversions between routes are not 1:1.

The second indication family — hemostatic prophylaxis in mild hemophilia A and most type-1 von Willebrand disease — was established in Mannucci, Ruggeri, Pareti & Capitanio, Lancet 1977, 1:869–872, the original Italian clinical report. Intravenous infusion of 0.3 µg/kg over 30 minutes produced a two- to three-fold rise in factor VIII coagulant activity in patients with mild hemophilia A and type-1 vWD, sufficient to support dental and minor surgical procedures without plasma concentrate exposure. The clinical importance of this finding for an HIV- and hepatitis-C-contaminated plasma-product era is hard to overstate, and the indication has remained core. Mannucci, Blood 1997, 90:2515–2521 reviewed the first two decades of hemostatic use and reported broad efficacy across mild hemophilia A, type-1 vWD, several platelet function disorders, and uremic and liver-disease bleeding. The hemostatic mechanism rests on V2-mediated release of pre-formed vWF and factor VIII from endothelial Weibel-Palade body stores; the peak elevation appears at roughly 30–60 minutes post-dose and falls back over the subsequent 6–12 hours. Tachyphylaxis is the structural limit: Mannucci, Bettega & Cattaneo, Br J Haematol 1992, 82:87–93 gave 0.3 µg/kg IV daily on four consecutive days to mild hemophilia A and type-1 vWD patients and documented an approximately 30% drop in factor VIII response after the second dose, with response then stable on days three and four — consistent with depletion of pre-formed endothelial stores faster than synthesis can replenish them. The clinical implication is that desmopressin is well suited to single-dose or short-course hemostatic cover (dental work, minor procedures, acute bleeds) but is not a substitute for factor concentrate in extended high-demand contexts.

The third indication is primary monosymptomatic nocturnal enuresis in children, where desmopressin restores the nocturnal antidiuretic signal that some affected children fail to mount. The largest synthesis is the Cochrane review Glazener & Evans, Cochrane Database Syst Rev 2002, CD002112 (41 trials, 2,760 children), which reported that desmopressin produced approximately 1.34 fewer wet nights per week versus placebo during treatment but that there was no durable difference after discontinuation — desmopressin is symptom-controlling, not curative. Bedwetting alarms produced more sustained long-term benefit but slower onset. The pediatric indication is the source of the most consequential safety inflection in the desmopressin record: the FDA in December 2007 withdrew the intranasal route's primary-nocturnal-enuresis indication after reviewing 61 postmarketing cases of hyponatremic seizures, two of them fatal, of which 41% occurred in pediatric patients receiving intranasal desmopressin most commonly for enuresis. The oral tablet retains the pediatric enuresis indication, with fluid restriction the load-bearing risk mitigation.

The fourth and most recent indication family is adult nocturia due to nocturnal polyuria, where desmopressin reduces nighttime urine production in patients with inadequate nocturnal AVP. Two FDA-approved formulations target this indication explicitly. Noctiva (intranasal, approved March 2017) is dosed at 0.83 µg or 1.66 µg as a single bedtime spray, with sex-differential dosing reflecting that women clear free water more slowly than men and accordingly face higher hyponatremia risk at equivalent doses. Nocdurna (sublingual ODT, approved June 2018) is dosed at 27.7 µg for women and 55.3 µg for men, taken one hour before bedtime. Both approvals carry a boxed warning for hyponatremia, both prohibit use in patients at high baseline risk of severe hyponatremia (excessive fluid intake, illnesses producing fluid or electrolyte imbalance, concurrent loop-diuretic or systemic-glucocorticoid therapy), and both reflect the sex-differential pharmacology in the label dose itself rather than as a downstream titration step. The geriatric nocturia population is the cohort with the narrowest therapeutic window: age-related decline in renal function prolongs desmopressin elimination, and the underlying patient population has higher baseline rates of hyponatremia-predisposing comorbidity.

A formulation distinction worth surfacing is the Stimate-versus-DDAVP nasal spray confusion. Stimate (the hemostatic intranasal product) delivers 150 µg per spray; the conventional DDAVP nasal spray (for diabetes insipidus) delivers 10 µg per spray — a 15-fold concentration difference between two products with similar brand visual identity, both containing the same molecule. The mismatch has been a documented source of prescribing and dispensing errors and is one reason the parenteral hemostatic route is often preferred in hospital settings.

The honest framing for the corpus: desmopressin is a sibling molecule to oxytocin on the posterior-pituitary nonapeptide axis, but the evidence profile is the inverse. Where oxytocin's intranasal-CNS-effects use case sits on a substantially contested literature, desmopressin's V2-receptor antidiuretic and endothelial-release indications sit on five decades of regulatory and clinical data. The peptide is on-label and widely prescribed; the relevant rigor is in dose selection, route, fluid restriction, and patient selection — not in whether the underlying pharmacology is real. See the peptides-and-hormones critic response for the broader framing of where labeled-drug peptides fit in this corpus, and the peptide injection technique reference for the subcutaneous-route considerations applicable to the hemostatic and CDI parenteral preparations.